Related references
Note: Only part of the references are listed.Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint
Daniel F. Hayes
JOURNAL OF CLINICAL ONCOLOGY (2021)
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1
F. Andre et al.
ANNALS OF ONCOLOGY (2021)
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1
Eva Maria Ciruelos et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Hope S. Rugo et al.
LANCET ONCOLOGY (2021)
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update
Beverly Moy et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
Preeti Narayan et al.
CLINICAL CANCER RESEARCH (2021)
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Mariya Rozenblit et al.
BREAST CANCER RESEARCH (2021)
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2 A Randomized Clinical Trial
George W. Sledge et al.
JAMA ONCOLOGY (2020)
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy
Peter A. Kaufman et al.
ONCOLOGIST (2020)
Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials
Jing Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Management of Male Breast Cancer: ASCO Guideline
Michael J. Hassett et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J. Gao et al.
LANCET ONCOLOGY (2020)
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Dennis J. Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.
Antonio Llombart-Cussac et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Nicholas C. Turner et al.
CLINICAL CANCER RESEARCH (2020)
Health-RelatedQuality of Life inMONARCH3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy inHR+,HER2-Advanced Breast Cancer
Matthew P. Goetz et al.
ONCOLOGIST (2020)
Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis
Jiani Zheng et al.
PLOS ONE (2020)
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Michela Piezzo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R. D. Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
J. K. Litton et al.
ANNALS OF ONCOLOGY (2020)
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
Nadia Harbeck et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer
Veronique Dieras et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer
Veronique Dieras et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
S. -A. Im et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis
Lynn J. Howie et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The Impact of Unconscious Bias in Healthcare: How to Recognize and Mitigate It
Jasmine R. Marcelin et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
Mark Robson et al.
EUROPEAN JOURNAL OF CANCER (2019)
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
H. S. Rugo et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G. N. Hortobagyi et al.
ANNALS OF ONCOLOGY (2018)
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
N. C. Turner et al.
ANNALS OF ONCOLOGY (2018)
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
H. S. Rugo et al.
ANNALS OF ONCOLOGY (2018)
First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2-advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
Wolfgang Janni et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib plus letrozole: results from MONALEESA-2
Sunil Verma et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Yunfu Deng et al.
CLINICAL BREAST CANCER (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy et al.
LANCET ONCOLOGY (2018)
The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis
Wu Ding et al.
MEDICINE (2018)
Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial
J. Ettl et al.
ANNALS OF ONCOLOGY (2018)
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials
Carlo Messina et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Palbociclib plus endocrine therapy in older women with HR+/HER2-advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
Hope S. Rugo et al.
EUROPEAN JOURNAL OF CANCER (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
Gabe S. Sonke et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2-advanced breast cancer in the randomized MONALEESA-2 trial
Joyce O'Shaughnessy et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits
L. J. Fallowfield et al.
SUPPORTIVE CARE IN CANCER (2017)
Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline
Timothy Gilligan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
Sibylle Loibl et al.
ONCOLOGIST (2017)
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
N. Harbeck et al.
ANNALS OF ONCOLOGY (2016)
Wilfully out of sight? A literature review on the effectiveness of cancer-related decision aids and implementation strategies
Anne Herrmann et al.
BMC MEDICAL INFORMATICS AND DECISION MAKING (2016)
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)
Sunil Verma et al.
ONCOLOGIST (2016)
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Catherine Van Poznak et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Breast Cancer Treatment Decision Making Among Latinas and Non-Latina Whites: A Communication Model Predicting Decisional Outcomes and Quality of Life
Betina Yanez et al.
HEALTH PSYCHOLOGY (2012)
Are Cancer-Related Decision Aids Effective? A Systematic Review and Meta-Analysis
Mary Ann O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
How quickly do systematic reviews go out of date? A survival analysis
Kaveh G. Shojania et al.
ANNALS OF INTERNAL MEDICINE (2007)
Share Paper
